Janney Capital Started Clearside Biomedical (CLSD)’s Rating On Jun 29, 2018.

June 29, 2018 - By Alice Fox

What’s Janney Capital’s Current Rate of Clearside Biomedical (CLSD)

On Thursday, 28 June was sent to investors analysts report in which Janney Capital has started coverage on shares of CLSD. The company issued “Buy” rating on Clearside Biomedical (CLSD)‘s stock.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Ratings Coverage

Total analysts of 7 have positions in Clearside Biomedical (CLSD) as follows: 7 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 30, 2018 according to StockzIntelligence Inc Clearside Biomedical has 9 analyst reports. On Tuesday, March 6 the rating was maintained by Wedbush with “Buy”. On Tuesday, February 20 the rating was maintained by Cowen & Co with “Buy”. On Tuesday, March 6 JP Morgan maintained the shares of CLSD in report with “Overweight” rating. In Tuesday, March 20 report Wedbush maintained the stock with “Buy” rating. On Wednesday, February 7 the company was maintained by Wedbush. On Monday, March 5 the stock of Clearside Biomedical, Inc. (NASDAQ:CLSD) earned “Buy” rating by Stifel Nicolaus.

CLSD is touching $10.87 during the last trading session, after increased 1.21%.Clearside Biomedical, Inc. has volume of 42,412 shares. Since June 29, 2017 CLSD has risen 77.87% and is uptrending. CLSD outperformed the S&P 500 by 65.30%.

Investors expect Clearside Biomedical, Inc. (NASDAQ:CLSD)’s quarterly earnings on August, 8., Zacks reports. earnings per share of $-0.57 is 5.56 % down from 2017’s $-0.54 EPS. Wall Street sees -8.06 % EPS growth as of August, 8.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye.The firm is valued at $347.26 million. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.Last it reported negative earnings. The firm also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases.

For more Clearside Biomedical, Inc. (NASDAQ:CLSD) news brought out recently go to: Benzinga.com, Seekingalpha.com, Globenewswire.com, Streetinsider.com or Benzinga.com. The titles are as follows: “58 Biggest Movers From Yesterday” brought out on June 01, 2018, “Clearside Bio completes enrollment in late-stage study of CLS-TA in retinal vein occlusion” on June 13, 2018, “Clearside Biomedical to Participate in 2018 JMP Securities Life Sciences Conference” with a publish date: June 11, 2018, “Pre-Open Movers 05/31: (MDGL) (VTVT) (GM) Higher; (CLSD) (CRSP) (DLTR) Lower (more…)” and the last “28 Stocks Moving In Thursday’s Pre-Market Session” with publication date: May 31, 2018.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: